Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AtezoCab in mCRPC with Non-Measurable Disease
NCT05168618Phase 2Active, not recruiting
- Sponsor
- University of Utah
- Start
- Mar 2022
- Primary completion
- Nov 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and cabozantinib in castration-resistant prostate cancer (CRPC), sponsored by University of Utah. Primary endpoint: Disease Control Rate at 24 weeks. Started Mar 2022; status: active, not recruiting.
02
Drugs
atezolizumabcabozantinib
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT05168618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05168618.